Autolus Therapeutics plc (NASDAQ: AUTL) started the day on February 19, 2021, with a price increase of 0.42% at $7.15. During the day, the stock rose to $7.40 and sunk to $7.01 before settling in for the price of $7.12 at the close. Taking a more long-term approach, AUTL posted a 52-week range of $3.00-$17.19.
Nevertheless, stock’s Earnings Per Share (EPS) this year is -448.30%. This publicly-traded company’s shares outstanding now amounts to $52.09 million, simultaneously with a float of $8.82 million. The organization now has a market capitalization sitting at $474.12 million. At the time of writing, stock’s 50-day Moving Average stood at $8.44, while the 200-day Moving Average is $11.89.
Autolus Therapeutics plc (AUTL) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Autolus Therapeutics plc’s current insider ownership accounts for 31.86%, in contrast to 18.50% institutional ownership.
Autolus Therapeutics plc (AUTL) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 9/29/2020, the organization reported -$0.72 earnings per share (EPS) for the three months, lower than the consensus estimate (set at -$0.71) by -$0.01. This company achieved a return on equity of -48.74. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.78 per share during the current fiscal year.
Autolus Therapeutics plc’s EPS decrease for this current 12-month fiscal period is -448.30% and is forecasted to reach -2.54 in the upcoming year.
Autolus Therapeutics plc (NASDAQ: AUTL) Trading Performance Indicators
Let’s observe the current performance indicators for Autolus Therapeutics plc (AUTL). It’s Quick Ratio in the last reported quarter now stands at 7.40. The Stock has managed to achieve an average true range (ATR) of 0.57. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 296.32.
In the same vein, AUTL’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.85, a figure that is expected to reach -0.77 in the next quarter, and analysts are predicting that it will be -2.54 at the market close of one year from today.
Technical Analysis of Autolus Therapeutics plc (AUTL)
If we take a close look at the recent performances of Autolus Therapeutics plc (NASDAQ: AUTL), its last 5-days Average volume was 1.99 million that shows progress from its year to date volume of 0.89 million. During the previous 9 days, stock’s Stochastic %D was recorded 28.74% While, its Average True Range was 0.59.
Raw Stochastic average of Autolus Therapeutics plc (AUTL) in the period of the previous 100 days is set at 9.69%, which indicates a major fall in contrast to 28.00% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 87.46% that was higher than 74.30% volatility it exhibited in the past 100-days period.